Spectrum Pharmaceuticals Inc

Spectrum Pharmaceuticals — Investor Presentation (January 2019)

29 slides from Spectrum Pharmaceuticals's investor presentation, Jan 7, 2019

  1. Slide 1: Spectrum Pharmaceuticals Investor Presentation January 2019

    A Biopharmaceutical Company Developing Targeted and Novel Therapies in Oncology Spectrum Pharmaceuticals January 2019 | Investor Presentation Joe Turgeon President and CEO Redefining Cancer Care Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements, within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date, regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainti

  3. Slide 3: Focus on Late Stage Pipeline

    POZIOTINIB ROLONTIS® (eflapegrastim) Tyrosine Kinase Inhibitor (TKI) targeting exon 20 mutations Results from ZENITH20 cohort 1 in 2H ‘19 Novel long-acting G-CSF for Chemotherapy-induced Neutropenia BLA submitted to FDA December 2018 Focus on Late Stage Pipeline Targeted & Novel Medicines

  4. Slide 4: Focus on Late Stage Pipeline Development Milestone Summary

    Tyrosine Kinase Inhibitor (TKI) targeting exon 20 mutations Novel long-acting G-CSF for Chemotherapy-induced Neutropenia Sep ’18 Oral presentation at IASLC World Conference on Lung Cancer Jan ’19 Enrollment completed in cohort 1 (EGFR) of ZENITH20 study H2 ’19 Results of ZENITH20 cohort 1 (EGFR) H2

  5. Slide 5: Poziotinib

    Poziotinib Tyrosine Kinase Inhibitor targeting exon 20 mutations Results from ZENITH20 cohort 1 in 2H 2019

  6. Slide 6: Exon 20 Mutations in NSCLC: A Critical Unmet Need

    Exon 20 Mutations in NSCLC A Critical Unmet Need No FDA approved targeted therapies NSCLC patients with exon 20 7,700 pts (US) 20,000+ (globally) Patients with non-lung exon 20 solid tumors 8,400 (US)

  7. Slide 7: Poziotinib Demonstrates Improvement Over Standards of Care

    Poziotinib Demonstrates Improvement Over Standards of Care Exon 20 (EGFR) Unselected population Exon 20 (EGFR)

  8. Slide 8: Poziotinib Efficacy in EGFR Exon 20 Mutant NSCLC

    JV Heymach, University of Texas MD Anderson Cancer Center, USA T790M * * * * * * * * * * * * * * * * * * * Germline T790M +exon20ins * Remains on treatment Poziotinib Efficacy in EGFR Exon 20 Mutant NSCLC 44 Evaluable Patients 43% ORR (confirmed) Heymach, IASLC 19th World Congress on Lung Cancer Ora

  9. Slide 9: Duration of Treatment for EGFR Exon 20

    Duration of Treatment for EGFR Exon 20 > 40% of patients remain on therapy (19 of 44 patients) 14% of patients have been on therapy for more than one year (6 of 44 patients) Heymach, IASLC 19th World Congress on Lung Cancer Oral Presentation, September 24, 2018

  10. Slide 10: Poziotinib Efficacy in HER2 Exon 20 Mutant NSCLC

    Poziotinib Efficacy in HER2 Exon 20 Mutant NSCLC * * Remains on treatment * * * * 12 Evaluable Patients 42% ORR (confirmed) Heymach, IASLC 19th World Congress on Lung Cancer Oral Presentation, September 24, 2018

  11. Slide 11: Treatment Related AEs in EGFR and HER2

    Treatment Related AEs in EGFR and HER2 in >10% of patients (N=63) EGFR related toxicities were manageable and consistent with the class Discontinuation due to poor tolerance was rare and seen in 3% of patients AE All Grade N (%) Grade 3 N(%) Grade 4 N(%) Grade 5 N(%) Diarrhea 44 (69.8%) 11 (17.5%) 0

  12. Slide 12: Poziotinib Efficacy in EGFR Cohort

    Poziotinib Efficacy in EGFR Cohort Subset of MD Anderson Investigator-Initiated Phase 2 Study Overall Results N ORR n (%) Confirmed Objective Response Rate (ORR) 30 12 (40.0) Disease Control Rate (DCR), n (%) 30 27 (90.0) Duration on Treatment (months) 30 6.6 Duration on Treatment > 6 months, n (%)

  13. Slide 13: ZENITH20: Spectrum Sponsored Pivotal Phase 2 Study

    First-line NSCLC in HER2 exon 20 (n=70) ZENITH20: Spectrum Sponsored Study Pivotal Phase 2 NSCLC Multicenter Study in US, EU, CA Each cohort is an independent study with pre-specified statistical hypotheses and power Primary Endpoint: Objective Response Rate Cohort 1 Enrollment Completed Results Exp

  14. Slide 14: Exon 20 Mutations in Various Tumor Types

    Exon 20 Mutations in Various Tumor Types Prevalence of Exon20 NSCLC in Key Markets Region Mutation Exon 20 Frequency (%) Total Number of Exon-20 NSCLC Patients/year US EGFR 2.1% 3.6% 7,700 HER2 1.5% EU EGFR 2.1% 3.6% 8,000 HER2 1.5% Japan EGFR 2.4% 6.4% 5,000 HER2 3.9% TOTAL Patients 20,700 Prevalen

  15. Slide 15: Poziotinib Leading the Way in Treatment of Exon 20 Mutations

    Poziotinib Leading the Way in the Treatment of exon 20 Mutations PAN-TUMOR SETTING COMBINATION THERAPY FIRST-LINE THERAPY IN NSCLC MD Anderson Spectrum Actively Pursue Poziotinib’s Full Potential PREVIOUSLY TREATED NSCLC

  16. Slide 16: Poziotinib – 2018 and 2019 Milestones

    Poziotinib – 2018 and 2019 Milestones Apr ’18 Publication of initial data of 11 pts with strong ORR (Nature Medicine) Apr ’18 Prevalence data shows promise in multiple solid tumors (AACR) May ’18 Diagnostic partnership with ThermoFisher + stronger licensing agreement with MD Anderson Sep ’18 Oral pr

  17. Slide 17: ROLONTIS (eflapegrastim)

    ROLONTIS® (eflapegrastim) Novel, long acting G-CSF for the Management of Chemotherapy-induced Neutropenia BLA submitted to FDA December 2018

  18. Slide 18: ROLONTIS is a Novel Product Targeting a Large Market

    ROLONTIS is a Novel Product Targeting a Large Market Targeting a $4 Billion Market BLA Submitted in Dec 2018

  19. Slide 19: Overall ROLONTIS Phase 3 Efficacy

    Overall ROLONTIS Phase 3 Efficacy *95% confidence intervals and p-value obtained from bootstrap sampling method ADVANCE (-301) RECOVER (-302) SPI-2012 N=196 Pegfilgrastim N=210 SPI-2012 N=118 Pegfilgrastim N=119 DSN (days) Mean (SD) Median (Range) 0.20 (0.503) 0 (0, 3) 0.35 (0.683) 0 (0, 3) 0.31 (0.

  20. Slide 20: ADVANCE Study Frequency of Severe Neutropenia in Cycle 1

    ADVANCE Study Frequency of Severe Neutropenia in Cycle 1 (ITT Population) *95% CI was calculated using Clopper-Pearson method 8.5% Absolute risk reduction of severe neutropenia in cycle 1 -8.5% Difference (CI -16.1, -0.2)

  21. Slide 21: Community Oncology is Critical in CIN

    * Data from Dec-16 to Nov-17 Community Oncology is Critical in CIN 21% Non-PHS Hospitals 45% Community Clinic 32% PHS 1% Federal 1% Pharmacy 1% Other LA-G-CSF Unit Volume by Segment

  22. Slide 22: Novel Treatment Offers Strong Position in Competitive Pricing Environment

    Novel Treatment Offers Strong Position in Competitive Pricing Environment Drug Costs Pricing Pressures, Price Transparency, Justification of Price Increases Competition in Medicare Marketplace Pressure on Provider Payment, Challenges to Buy & Bill Model Challenging Pricing Constructs, Reference Pric

  23. Slide 23: ROLONTIS Launch Readiness Underway

    Supply Chain / Manufacturing Inventory build Filling/packaging Commercialization Develop promotional materials / channel strategy Medical Science Liaison customer engagement Payer engagement Sales force preparation ROLONTIS Launch Readiness Underway

  24. Slide 24: ROLONTIS – 2018 and 2019 Milestones

    ROLONTIS – 2018 and 2019 Milestones Feb ’18 ADVANCE study meets primary endpoint Jun ’18 RECOVER study meets primary endpoint Aug ’18 Positive pre-BLA meeting with FDA Q4 ’18 US BLA filing Q1 ’19 FDA acceptance of BLA file 2019 US launch readiness Q4 ’19 Potential FDA decision ✓ ✓ ✓ ✓

  25. Slide 25: Thank you

    Thank you Redefining Cancer Care Redefining Cancer Care

  26. Slide 26: Non-GAAP Financial Measures

    Non-GAAP Financial Measures In this press release, Spectrum reports certain historical results that have not been prepared in accordance with generally accepted accounting principles (GAAP), including non-GAAP product sales, net and license fees and service revenue, non-GAAP selling, general and adm

  27. Slide 27: Spectrum Pharmaceuticals Non-GAAP Reconciliation

    SPECTRUM PHARMACEUTICALS, INC. (a thousands, expect per share amounts) Three Months Ended ‘Nine Months Ended “ree 201 2017 @)_ GAAP product sales, net & license fees and service revenue Ss 25268 os s a S$ 79,930 $ 99,797 = 01) 6.000 325268 § ae S_7929 $94,797 @) GAAP selling, general and administrat

  28. Slide 28: Condensed Consolidated Statements of Operations

    aN "ALS, INC. Condensed Consolidated Statements of Operations (thousands, share amovats) ‘Total other (expense) income Loss before income taxes (Provision) benefit for income taxes ‘tose Net loss per share: Diluted Weighted average shares outstanding Basic Died ‘Three Months Ended ‘Nine Months Ended

  29. Slide 29: Spectrum Pharmaceuticals Balance Sheet

    SPECTRUM PHARMACEUTICALS, INC. September 30, a s a7 § s December 31, 207

Spectrum Pharmaceuticals — Investor Presentation (January 2019) on 6ix